A low-dose triple polypill containing telmisartan, amlodipine, and indapamide led to clinically meaningful improvements in ...

某地民宿的男厕所，风景堪比五星级酒店女，网友：为啥不拍女厕所 ...

王楚钦为国出征，奥特曼打怪兽专治不服！

Cranberry juice offers numerous health benefits like preventing UTIs, boosting immunity, promoting heart and skin health, and ...

石药集团（股票代码：01093）近日与全球制药巨头阿斯利康签订了独家授权协议，共同致力于脂蛋白 (a)抑制剂YS2302018及其相关产品的全球开发、制造与商业化进程。根据该协议条款，石药集团将先行获得1亿美元的预付款作为合作启动资金。

Apolipoprotein B/A1 ratio was associated with an increased risk for both macrovascular and microvascular events in type 2 diabetes.

文| 氨基观察 阿斯利康继续在华淘金。 10月7日，阿斯利康与石药集团达成协议，推进开发一款临床前创新小分子脂蛋白(a)抑制剂YS2302018。

More recently, cardiologists like Dr. Allan Sniderman of McGill University in Montreal have been calling for testing what he ...

The following is a summary of “Coronary Artery Calcification Progression in Patients With Systemic Lupus Erythematosus,” ...

圣地亚哥 - 生物制药公司Viking Therapeutics, Inc. (NASDAQ: VKTX)宣布其VK0214治疗X连锁肾上腺脑白质营养不良(X-ALD)的1b期临床试验取得积极结果。研究发现,该药物在连续28天每日给药期间安全性良好,耐受性佳。与安慰剂相比,还观察到极长链脂肪酸(VLCFAs)和其他血浆脂质显著降低。 这项随机、双盲、安慰剂对照试验评估了VK0214对X-ALD生物 ...

2. Compared with placebo, the plozasiran groups also saw reductions in apolipoprotein C3 (APOC3), non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B (apoB) levels. Evidence Rating ...